CUMYL-PINACA
Synthetic cannabinoid
CUMYL-PINACA | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | 1400742-14-7 |
PubChem | 118796952 |
DrugBank | |
ChemSpider | 29762284 |
KEGG |
CUMYL-PINACA is a synthetic cannabinoid that has been used as an active ingredient in synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system.
Chemical Structure and Properties
CUMYL-PINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide. The compound has a molecular formula of C22H25N3O and a molecular weight of 347.46 g/mol.
Pharmacology
CUMYL-PINACA acts as a potent agonist at the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, appetite, and mood. The activation of these receptors by CUMYL-PINACA can lead to effects similar to those produced by tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Legal Status
CUMYL-PINACA is classified as a Schedule I substance under the Controlled Substances Act in the United States, indicating that it is considered to have a high potential for abuse and no accepted medical use. In the United Kingdom, it is classified as a Class B drug under the Misuse of Drugs Act 1971. In Canada, it is listed under Schedule II of the Controlled Drugs and Substances Act.
Health Risks and Toxicity
The use of synthetic cannabinoids like CUMYL-PINACA has been associated with a range of adverse health effects, including tachycardia, hypertension, nausea, vomiting, hallucinations, and seizures. Due to its potency and the variability in the composition of synthetic cannabis products, the risk of overdose and severe toxicity is significant.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD